ArticleTranslational pediatrics2026
Efficacy and influencing factors of recombinant human growth hormone therapy in children with Turner syndrome: a single-center retrospective cohort study.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Real-world evidence regarding the optimal initiation timing and safety of recombinant human growth hormone (rhGH) in children with Turner syndrome (TS) remains limited. This study aimed to evaluate the efficacy of rhGH therapy in children with TS and to identify clinically relevant factors influencing treatment outcomes, thereby providing evidence to inform individualized therapeutic strategies. Methods: This retrospective cohort study included 50 pediatric patients with TS (3-14 years) who received rhGH therapy for ≥6 months. Eligibility criteria included a confirmed TS karyotype and height <-2 standard deviations (SDs). Baseline characteristics, laboratory parameters, and karyotypes were recorded. Patients were followed up every 6 months for up to 36 months, with height-related indicators [height standard deviation score (HtSDS), change in HtSDS (ΔHtSDS), growth velocity (GV)] and safety parameters [glycated hemoglobin (HbA1c), homeostatic model assessment for insulin resistance (HOMA-IR)] monitored. We used a generalized estimating equation (GEE) model to identify factors associated with rhGH treatment efficacy and then examined the interaction between follow-up duration and age at treatment initiation. Results: Baseline characteristics showed a median age of 7 [5-11] years and a mean HtSDS of -3.18±0.93. After 36 months of treatment, the mean height increased from 114.50±14.90 cm at baseline to 132.82±11.77 cm, whereas HtSDS improved to -1.80±0.99 (mean ΔHtSDS 1.20±0.67). Safety evaluation in a stable 12-month cohort (n=33) showed stable HbA1c levels (P=0.87) and a physiological increase in HOMA-IR (P=0.049) within the normal clinical range. GEE analysis revealed that treatment duration was positively correlated with HtSDS and ΔHtSDS, but negatively correlated with GV (all P<0.05). Baseline HtSDS was positively associated with follow-up HtSDS (β=0.797, P<0.001). Interaction analysis indicated a significant interaction between initiation age and follow-up duration: patients who started therapy earlier exhibited more rapid increases in HtSDS and ΔHtSDS during the early phase (6-12 months), whereas those with later initiation showed a greater decline in GV at 36 months. Conclusions: rhGH therapy appears to be effective and safe for enhancing linear growth in children with TS. The therapeutic response is time-dependent and appears to be optimized by earlier initiation and higher baseline height.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.